 Home > Medical News > Latest Medical News > New drug application for RTK inhibitor for the treatment of renal cell carcinoma

New drug application for RTK inhibitor for the treatment of renal cell carcinoma

 Last Update: 2022-01-10
 Source: Internet
 Author: User

Tags

thorazine drug

cell power

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, Allarity Therapeutics announced that it has submitted a New Drug Application (NDA) to the US FDA to seek approval of the receptor tyrosine kinase (RTK) inhibitor dovitinib for the third-line treatment of renal cell carcinoma (RCC)

Dovitinib is a small molecule RTK inhibitor that has previously shown clinical activity in many cancer indications, including RCC, gastrointestinal stromal tumor (GIST), endometrial cancer, metastatic breast cancer and hepatocellular carcinoma ( HCC)

And Allarity's DRP companion diagnostic technology platform, by analyzing the tumor cell RNA of more than 3000 patient tumors and the gene expression data of multiple drugs, is expected to predict whether specific cancer patients are likely to be treated with dovitinib in addition to a wide range of anticancer drugs.

Dovitinib-DRP companion diagnosis is expected to be used to identify patients with advanced RCC who are likely to have a high response to dovitinib through the gene expression characteristics of their tumors

Reference materials:

[1] Allarity Therapeutics Submits New Drug Application (NDA) to the US FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC).

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.